Alli Weight Loss Drug Launched By GSK - Orlistat
Alli a weight loss drug has been launched by GSK. It is the first clinically proven over-the-counter weight loss aid to be available in pharmacies across the UK and Europe.
Pharmacists note that it is a category “p” product and will be charged at around £50 monthly, and have been informed to restrict sales to suitable customers only.
GSK is running a multi-million pound investment in pharmacy training, consumer marketing and a behavioural support programme. this will include access to an online Alli weight-loss programme, provicing support and tools to help people follow a sensible diet and encourage sustainable weight loss.
Manfred Scheske, president GSK Consumer Healthcare Europe, said: “Alli offers adults a real opportunity for losing weight. Alli has been well received by millions of people in the US and we are very excited about the number of people it could help across Europe achieve their goal to lose weight.”
GSK received a non-prescription European licence for the drug in January, marking the first time the Commission has approved a non-prescription product for weight loss. Alli (orlistat 60mg) is a lower-dose version of Roche’s prescription drug Xenical, which has been available for more than 10 years.
Alli and Xeniccal contain the same active ingredient, which acts locally within the digestive system to prevent absorption of fat. It does this by allowing fat to quickly pass straight through the body, prompting some unpleasant side effects in people who take the drug but contain to over-eat.
The drug is indicated for use in adults with a Body Mass Index (BMI) of 28 or more on a reduced calorie, lower-fat diet.
It was launched in the US in June 2007 and it is now the seventh-largest OTC brand in the country.
Clinical trials data shows that Alli, when used in conjunction with a reduced calorie, lower-fat diet, can help people lose 50% more weight than by dieting alone.